General
Preferred name
CAPTOPRIL
Synonyms
SQ 14225 ()
SQ-14534 ()
SA333 ()
SQ 14225,Capoten ()
Captopril-d3 ()
Apopril ()
C09AA01 ()
SQ -14225 ()
Hyteneze 25 ()
Lopril ()
Hyteneze 12.5 ()
Hyteneze 50 ()
Acepril ()
Noyada ()
Captoprilum ()
Farcopril ()
NSC-757419 ()
Hypopress ()
SA-333 ()
SQ-14225 ()
Zapto ()
Kaplon ()
Captomax ()
Mepha ()
Tensobon ()
Tensiomin ()
Capoten ()
SQ 14,225 ()
Ecopace ()
Garranil ()
Captomex ()
P&D ID
PD001635
CAS
62571-86-2
1356383-38-4
Tags
available
drug
Approved by
FDA
First approval
1981
Drug indication
Congestive heart failure
Hypertension
Coronavirus Disease 2019 (COVID-19)
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Captopril is a potent, competitive angiotensin-converting enzyme (ACE) inhibitor, and is one of the few that is not a prodrug. (GtoPdb)
DESCRIPTION Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 ¦ÌM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-¦Â-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 ¦ÌM[1][2][3].
PRICE 29
DESCRIPTION Angiotensin-converting enzyme (ACE) inhibitor; antihypertensive (LOPAC library)
DESCRIPTION Captopril is an ACE inhibitor used for the management of essential or renovascular hypertension, congestive heart failure, left ventricular dysfunction following myocardial infarction, and nephropathy. (Enamine Bioactive Compounds)
DESCRIPTION Captopril (SA333) is a potent and specific inhibitor of peptidyl-dipeptidase A. It blocks the conversion of angiotensin I to angiotensin II, a vasoconstrictor and important regulator of arterial blood pressure. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
4
Compound Sets
31
AdooQ Bioactive Compound Library
A11738
Cayman Chemical Bioactives
15313
25235
ChEMBL Approved Drugs
CHEMBL1560
ChEMBL Drugs
CHEMBL1560
Concise Guide to Pharmacology 2017/18
5158
Concise Guide to Pharmacology 2019/20
5158
Concise Guide to Pharmacology 2021/22
5158
Concise Guide to Pharmacology 2023/24
5158
Drug Repurposing Hub
DrugBank
DB01197
DrugBank Approved Drugs
DB01197
DrugCentral
484
DrugCentral Approved Drugs
484
DrugMAP
DM458UM
DMMZDJ6
DrugMAP Approved Drugs
DM458UM
Enamine Bioactive Compounds
EBC-02058
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101434
Guide to Pharmacology
5158
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1560
MedChem Express Bioactive Compound Library
HY-B0368
NCATS Inxight Approved Drugs
9G64RSX1XD
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
captopril-capoten
TargetMol Bioactive Compound Library
T1462
The Spectrum Collection
ZINC Tool Compounds
ZINC000000057001
External IDs
46
Properties
(calculated by RDKit )
Molecular Weight
217.08
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
0
cLogP
0.63
TPSA
57.61
Fraction CSP3
0.78
Chiral centers
2.0
Largest ring
5.0
QED
0.68
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
ACE
Indication
hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy
Disease Area
cardiology, endocrinology, nephrology
Target
ACE, LTA4H, MMP2, MMP9
Angiotensin-converting Enzyme (ACE)
ACE,RAAS
MOA
angiotensin converting enzyme inhibitor
Therapeutic Class
Antihypertensive Agents
Antiviral Agents
Pathway
Metabolic Enzyme/Protease
Endocrinology/Hormones
Source data